nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—Retinal vein occlusion—Vemurafenib—melanoma	0.0693	0.137	CcSEcCtD
Raloxifene—Dyclonine—SCN10A—melanoma	0.0198	1	CrCbGaD
Raloxifene—Ovarian cancer—Docetaxel—melanoma	0.017	0.0337	CcSEcCtD
Raloxifene—CYP3A4—Temozolomide—melanoma	0.0134	0.576	CbGbCtD
Raloxifene—Thromboembolic event—Docetaxel—melanoma	0.011	0.0217	CcSEcCtD
Raloxifene—Neoplasm malignant—Vemurafenib—melanoma	0.0102	0.0201	CcSEcCtD
Raloxifene—CYP3A4—Vemurafenib—melanoma	0.00737	0.316	CbGbCtD
Raloxifene—Deep vein thrombosis—Temozolomide—melanoma	0.0073	0.0144	CcSEcCtD
Raloxifene—Embolism—Temozolomide—melanoma	0.00692	0.0137	CcSEcCtD
Raloxifene—Arthritis—Vemurafenib—melanoma	0.00649	0.0128	CcSEcCtD
Raloxifene—Tenderness—Bleomycin—melanoma	0.00603	0.0119	CcSEcCtD
Raloxifene—Vaginal haemorrhage—Temozolomide—melanoma	0.006	0.0119	CcSEcCtD
Raloxifene—Cystitis noninfective—Bleomycin—melanoma	0.00514	0.0102	CcSEcCtD
Raloxifene—Breast pain—Temozolomide—melanoma	0.00509	0.0101	CcSEcCtD
Raloxifene—Cystitis—Bleomycin—melanoma	0.00508	0.0101	CcSEcCtD
Raloxifene—Deep vein thrombosis—Docetaxel—melanoma	0.00485	0.0096	CcSEcCtD
Raloxifene—Bladder pain—Bleomycin—melanoma	0.00476	0.00941	CcSEcCtD
Raloxifene—Embolism—Docetaxel—melanoma	0.0046	0.0091	CcSEcCtD
Raloxifene—Pulmonary embolism—Carmustine—melanoma	0.00459	0.00909	CcSEcCtD
Raloxifene—Pulmonary embolism—Temozolomide—melanoma	0.00444	0.00878	CcSEcCtD
Raloxifene—Vaginal inflammation—Temozolomide—melanoma	0.00444	0.00878	CcSEcCtD
Raloxifene—Oedema peripheral—Vemurafenib—melanoma	0.0043	0.0085	CcSEcCtD
Raloxifene—Connective tissue disorder—Vemurafenib—melanoma	0.00429	0.00848	CcSEcCtD
Raloxifene—Neuralgia—Docetaxel—melanoma	0.00425	0.00841	CcSEcCtD
Raloxifene—Vaginal infection—Temozolomide—melanoma	0.00419	0.00829	CcSEcCtD
Raloxifene—Cardiac disorder—Vemurafenib—melanoma	0.00405	0.00801	CcSEcCtD
Raloxifene—Angiopathy—Vemurafenib—melanoma	0.00396	0.00783	CcSEcCtD
Raloxifene—Arthritis—Bleomycin—melanoma	0.00393	0.00778	CcSEcCtD
Raloxifene—Cerebrovascular accident—Bleomycin—melanoma	0.0039	0.00771	CcSEcCtD
Raloxifene—Diabetes mellitus—Carmustine—melanoma	0.00383	0.00758	CcSEcCtD
Raloxifene—Gastroenteritis—Temozolomide—melanoma	0.00364	0.00719	CcSEcCtD
Raloxifene—Hot flush—Temozolomide—melanoma	0.00345	0.00681	CcSEcCtD
Raloxifene—Menopausal symptoms—Temozolomide—melanoma	0.00342	0.00676	CcSEcCtD
Raloxifene—Cough—Vemurafenib—melanoma	0.00331	0.00656	CcSEcCtD
Raloxifene—Myalgia—Vemurafenib—melanoma	0.00323	0.0064	CcSEcCtD
Raloxifene—Arthralgia—Vemurafenib—melanoma	0.00323	0.0064	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00321	0.00635	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00321	0.00635	CcSEcCtD
Raloxifene—Infection—Vemurafenib—melanoma	0.00308	0.00609	CcSEcCtD
Raloxifene—Nervous system disorder—Vemurafenib—melanoma	0.00304	0.00601	CcSEcCtD
Raloxifene—Skin disorder—Vemurafenib—melanoma	0.00301	0.00596	CcSEcCtD
Raloxifene—Pneumonia—Bleomycin—melanoma	0.00296	0.00586	CcSEcCtD
Raloxifene—Pulmonary embolism—Docetaxel—melanoma	0.00295	0.00584	CcSEcCtD
Raloxifene—Blood pressure increased—Docetaxel—melanoma	0.00295	0.00584	CcSEcCtD
Raloxifene—Breast disorder—Temozolomide—melanoma	0.00291	0.00576	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Temozolomide—melanoma	0.0029	0.00574	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00282	0.00559	CcSEcCtD
Raloxifene—Pneumonia—Dactinomycin—melanoma	0.00276	0.00546	CcSEcCtD
Raloxifene—Bronchitis—Temozolomide—melanoma	0.00268	0.0053	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vemurafenib—melanoma	0.00268	0.00529	CcSEcCtD
Raloxifene—Hypoaesthesia—Bleomycin—melanoma	0.00263	0.0052	CcSEcCtD
Raloxifene—Pneumonia—Carmustine—melanoma	0.00259	0.00511	CcSEcCtD
Raloxifene—Depression—Carmustine—melanoma	0.00256	0.00507	CcSEcCtD
Raloxifene—Weight increased—Temozolomide—melanoma	0.00254	0.00501	CcSEcCtD
Raloxifene—CYP3A4—Docetaxel—melanoma	0.00253	0.108	CbGbCtD
Raloxifene—Urinary tract infection—Carmustine—melanoma	0.0025	0.00494	CcSEcCtD
Raloxifene—Pneumonia—Temozolomide—melanoma	0.0025	0.00494	CcSEcCtD
Raloxifene—Depression—Temozolomide—melanoma	0.00248	0.0049	CcSEcCtD
Raloxifene—Flushing—Bleomycin—melanoma	0.00245	0.00485	CcSEcCtD
Raloxifene—Body temperature increased—Vemurafenib—melanoma	0.00245	0.00485	CcSEcCtD
Raloxifene—Pharyngitis—Dactinomycin—melanoma	0.00245	0.00484	CcSEcCtD
Raloxifene—Urinary tract infection—Temozolomide—melanoma	0.00241	0.00478	CcSEcCtD
Raloxifene—Sinusitis—Temozolomide—melanoma	0.00233	0.00461	CcSEcCtD
Raloxifene—Hypoaesthesia—Carmustine—melanoma	0.0023	0.00454	CcSEcCtD
Raloxifene—Hot flush—Docetaxel—melanoma	0.00229	0.00453	CcSEcCtD
Raloxifene—Flushing—Dactinomycin—melanoma	0.00229	0.00453	CcSEcCtD
Raloxifene—Oedema peripheral—Carmustine—melanoma	0.00227	0.0045	CcSEcCtD
Raloxifene—Menopausal symptoms—Docetaxel—melanoma	0.00227	0.00449	CcSEcCtD
Raloxifene—Connective tissue disorder—Carmustine—melanoma	0.00227	0.00448	CcSEcCtD
Raloxifene—Hypoaesthesia—Temozolomide—melanoma	0.00222	0.00439	CcSEcCtD
Raloxifene—Pharyngitis—Temozolomide—melanoma	0.00221	0.00438	CcSEcCtD
Raloxifene—Urinary tract disorder—Temozolomide—melanoma	0.0022	0.00436	CcSEcCtD
Raloxifene—Oedema peripheral—Temozolomide—melanoma	0.0022	0.00434	CcSEcCtD
Raloxifene—Connective tissue disorder—Temozolomide—melanoma	0.00219	0.00433	CcSEcCtD
Raloxifene—Urethral disorder—Temozolomide—melanoma	0.00219	0.00432	CcSEcCtD
Raloxifene—Flushing—Carmustine—melanoma	0.00214	0.00424	CcSEcCtD
Raloxifene—Diarrhoea—Vemurafenib—melanoma	0.00212	0.00419	CcSEcCtD
Raloxifene—Migraine—Docetaxel—melanoma	0.00211	0.00417	CcSEcCtD
Raloxifene—Flushing—Temozolomide—melanoma	0.00207	0.00409	CcSEcCtD
Raloxifene—Cardiac disorder—Temozolomide—melanoma	0.00207	0.00409	CcSEcCtD
Raloxifene—Dizziness—Vemurafenib—melanoma	0.00205	0.00405	CcSEcCtD
Raloxifene—Angiopathy—Temozolomide—melanoma	0.00202	0.004	CcSEcCtD
Raloxifene—Cough—Bleomycin—melanoma	0.00201	0.00397	CcSEcCtD
Raloxifene—Vomiting—Vemurafenib—melanoma	0.00197	0.0039	CcSEcCtD
Raloxifene—Myalgia—Bleomycin—melanoma	0.00196	0.00387	CcSEcCtD
Raloxifene—Chest pain—Bleomycin—melanoma	0.00196	0.00387	CcSEcCtD
Raloxifene—Rash—Vemurafenib—melanoma	0.00195	0.00387	CcSEcCtD
Raloxifene—Dermatitis—Vemurafenib—melanoma	0.00195	0.00386	CcSEcCtD
Raloxifene—Headache—Vemurafenib—melanoma	0.00194	0.00384	CcSEcCtD
Raloxifene—Breast disorder—Docetaxel—melanoma	0.00194	0.00383	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00193	0.00382	CcSEcCtD
Raloxifene—Infection—Bleomycin—melanoma	0.00187	0.00369	CcSEcCtD
Raloxifene—Nausea—Vemurafenib—melanoma	0.00184	0.00364	CcSEcCtD
Raloxifene—Thrombocytopenia—Bleomycin—melanoma	0.00184	0.00364	CcSEcCtD
Raloxifene—Myalgia—Dactinomycin—melanoma	0.00183	0.00361	CcSEcCtD
Raloxifene—Vertigo—Temozolomide—melanoma	0.00174	0.00345	CcSEcCtD
Raloxifene—Infection—Dactinomycin—melanoma	0.00174	0.00344	CcSEcCtD
Raloxifene—Thrombocytopenia—Dactinomycin—melanoma	0.00171	0.00339	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Bleomycin—melanoma	0.00171	0.00338	CcSEcCtD
Raloxifene—Chest pain—Carmustine—melanoma	0.00171	0.00338	CcSEcCtD
Raloxifene—Myalgia—Carmustine—melanoma	0.00171	0.00338	CcSEcCtD
Raloxifene—Cough—Temozolomide—melanoma	0.00169	0.00335	CcSEcCtD
Raloxifene—Weight increased—Docetaxel—melanoma	0.00169	0.00333	CcSEcCtD
Raloxifene—Pneumonia—Docetaxel—melanoma	0.00166	0.00329	CcSEcCtD
Raloxifene—Myalgia—Temozolomide—melanoma	0.00165	0.00327	CcSEcCtD
Raloxifene—Arthralgia—Temozolomide—melanoma	0.00165	0.00327	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00164	0.00325	CcSEcCtD
Raloxifene—Infection—Carmustine—melanoma	0.00163	0.00322	CcSEcCtD
Raloxifene—Pain—Bleomycin—melanoma	0.00161	0.00318	CcSEcCtD
Raloxifene—Conjunctivitis—Docetaxel—melanoma	0.00161	0.00318	CcSEcCtD
Raloxifene—Thrombocytopenia—Carmustine—melanoma	0.00161	0.00317	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dactinomycin—melanoma	0.0016	0.00316	CcSEcCtD
Raloxifene—Infection—Temozolomide—melanoma	0.00157	0.00311	CcSEcCtD
Raloxifene—Nervous system disorder—Temozolomide—melanoma	0.00155	0.00307	CcSEcCtD
Raloxifene—Thrombocytopenia—Temozolomide—melanoma	0.00155	0.00307	CcSEcCtD
Raloxifene—Skin disorder—Temozolomide—melanoma	0.00154	0.00304	CcSEcCtD
Raloxifene—Hyperhidrosis—Temozolomide—melanoma	0.00153	0.00303	CcSEcCtD
Raloxifene—Pain—Dactinomycin—melanoma	0.0015	0.00296	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Carmustine—melanoma	0.00149	0.00295	CcSEcCtD
Raloxifene—Rhinitis—Docetaxel—melanoma	0.00149	0.00294	CcSEcCtD
Raloxifene—Body temperature increased—Bleomycin—melanoma	0.00148	0.00294	CcSEcCtD
Raloxifene—Insomnia—Carmustine—melanoma	0.00148	0.00293	CcSEcCtD
Raloxifene—Hypoaesthesia—Docetaxel—melanoma	0.00148	0.00292	CcSEcCtD
Raloxifene—Pharyngitis—Docetaxel—melanoma	0.00147	0.00291	CcSEcCtD
Raloxifene—Urinary tract disorder—Docetaxel—melanoma	0.00146	0.0029	CcSEcCtD
Raloxifene—Oedema peripheral—Docetaxel—melanoma	0.00146	0.00289	CcSEcCtD
Raloxifene—Connective tissue disorder—Docetaxel—melanoma	0.00146	0.00288	CcSEcCtD
Raloxifene—Urethral disorder—Docetaxel—melanoma	0.00145	0.00287	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Temozolomide—melanoma	0.00144	0.00285	CcSEcCtD
Raloxifene—Insomnia—Temozolomide—melanoma	0.00143	0.00283	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dactinomycin—melanoma	0.00143	0.00283	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Carmustine—melanoma	0.00142	0.0028	CcSEcCtD
Raloxifene—Pain—Carmustine—melanoma	0.0014	0.00277	CcSEcCtD
Raloxifene—Dyspepsia—Temozolomide—melanoma	0.00139	0.00276	CcSEcCtD
Raloxifene—Body temperature increased—Dactinomycin—melanoma	0.00138	0.00274	CcSEcCtD
Raloxifene—Abdominal pain—Dactinomycin—melanoma	0.00138	0.00274	CcSEcCtD
Raloxifene—Cardiac disorder—Docetaxel—melanoma	0.00138	0.00272	CcSEcCtD
Raloxifene—Flushing—Docetaxel—melanoma	0.00138	0.00272	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Temozolomide—melanoma	0.00137	0.00271	CcSEcCtD
Raloxifene—Pain—Temozolomide—melanoma	0.00135	0.00268	CcSEcCtD
Raloxifene—Angiopathy—Docetaxel—melanoma	0.00135	0.00266	CcSEcCtD
Raloxifene—Gastrointestinal pain—Carmustine—melanoma	0.00134	0.00265	CcSEcCtD
Raloxifene—Abdominal pain—Carmustine—melanoma	0.0013	0.00256	CcSEcCtD
Raloxifene—Body temperature increased—Carmustine—melanoma	0.0013	0.00256	CcSEcCtD
Raloxifene—Gastrointestinal pain—Temozolomide—melanoma	0.0013	0.00256	CcSEcCtD
Raloxifene—Body temperature increased—Temozolomide—melanoma	0.00125	0.00248	CcSEcCtD
Raloxifene—Abdominal pain—Temozolomide—melanoma	0.00125	0.00248	CcSEcCtD
Raloxifene—Muscle spasms—Docetaxel—melanoma	0.00124	0.00245	CcSEcCtD
Raloxifene—Diarrhoea—Dactinomycin—melanoma	0.0012	0.00237	CcSEcCtD
Raloxifene—Vomiting—Bleomycin—melanoma	0.00119	0.00236	CcSEcCtD
Raloxifene—Rash—Bleomycin—melanoma	0.00118	0.00234	CcSEcCtD
Raloxifene—Dermatitis—Bleomycin—melanoma	0.00118	0.00234	CcSEcCtD
Raloxifene—Syncope—Docetaxel—melanoma	0.00116	0.00229	CcSEcCtD
Raloxifene—Loss of consciousness—Docetaxel—melanoma	0.00113	0.00224	CcSEcCtD
Raloxifene—Cough—Docetaxel—melanoma	0.00113	0.00223	CcSEcCtD
Raloxifene—Diarrhoea—Carmustine—melanoma	0.00112	0.00222	CcSEcCtD
Raloxifene—Nausea—Bleomycin—melanoma	0.00112	0.00221	CcSEcCtD
Raloxifene—Vomiting—Dactinomycin—melanoma	0.00111	0.0022	CcSEcCtD
Raloxifene—Rash—Dactinomycin—melanoma	0.0011	0.00218	CcSEcCtD
Raloxifene—Chest pain—Docetaxel—melanoma	0.0011	0.00217	CcSEcCtD
Raloxifene—Arthralgia—Docetaxel—melanoma	0.0011	0.00217	CcSEcCtD
Raloxifene—Myalgia—Docetaxel—melanoma	0.0011	0.00217	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00109	0.00216	CcSEcCtD
Raloxifene—Dizziness—Carmustine—melanoma	0.00108	0.00214	CcSEcCtD
Raloxifene—Diarrhoea—Temozolomide—melanoma	0.00108	0.00214	CcSEcCtD
Raloxifene—Dizziness—Temozolomide—melanoma	0.00105	0.00207	CcSEcCtD
Raloxifene—Infection—Docetaxel—melanoma	0.00105	0.00207	CcSEcCtD
Raloxifene—Vomiting—Carmustine—melanoma	0.00104	0.00206	CcSEcCtD
Raloxifene—Nausea—Dactinomycin—melanoma	0.00104	0.00206	CcSEcCtD
Raloxifene—Shock—Docetaxel—melanoma	0.00104	0.00205	CcSEcCtD
Raloxifene—Rash—Carmustine—melanoma	0.00103	0.00204	CcSEcCtD
Raloxifene—Nervous system disorder—Docetaxel—melanoma	0.00103	0.00204	CcSEcCtD
Raloxifene—Dermatitis—Carmustine—melanoma	0.00103	0.00204	CcSEcCtD
Raloxifene—Thrombocytopenia—Docetaxel—melanoma	0.00103	0.00204	CcSEcCtD
Raloxifene—Headache—Carmustine—melanoma	0.00103	0.00203	CcSEcCtD
Raloxifene—Skin disorder—Docetaxel—melanoma	0.00102	0.00202	CcSEcCtD
Raloxifene—Vomiting—Temozolomide—melanoma	0.00101	0.00199	CcSEcCtD
Raloxifene—Rash—Temozolomide—melanoma	0.000999	0.00198	CcSEcCtD
Raloxifene—Dermatitis—Temozolomide—melanoma	0.000998	0.00197	CcSEcCtD
Raloxifene—Headache—Temozolomide—melanoma	0.000992	0.00196	CcSEcCtD
Raloxifene—Nausea—Carmustine—melanoma	0.000974	0.00193	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Docetaxel—melanoma	0.00096	0.0019	CcSEcCtD
Raloxifene—Insomnia—Docetaxel—melanoma	0.000953	0.00188	CcSEcCtD
Raloxifene—Nausea—Temozolomide—melanoma	0.000941	0.00186	CcSEcCtD
Raloxifene—Dyspepsia—Docetaxel—melanoma	0.000927	0.00183	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Docetaxel—melanoma	0.00091	0.0018	CcSEcCtD
Raloxifene—Pain—Docetaxel—melanoma	0.000901	0.00178	CcSEcCtD
Raloxifene—Gastrointestinal pain—Docetaxel—melanoma	0.000861	0.0017	CcSEcCtD
Raloxifene—Body temperature increased—Docetaxel—melanoma	0.000833	0.00165	CcSEcCtD
Raloxifene—Abdominal pain—Docetaxel—melanoma	0.000833	0.00165	CcSEcCtD
Raloxifene—Diarrhoea—Docetaxel—melanoma	0.000721	0.00143	CcSEcCtD
Raloxifene—Dizziness—Docetaxel—melanoma	0.000697	0.00138	CcSEcCtD
Raloxifene—Vomiting—Docetaxel—melanoma	0.00067	0.00132	CcSEcCtD
Raloxifene—Rash—Docetaxel—melanoma	0.000664	0.00131	CcSEcCtD
Raloxifene—Dermatitis—Docetaxel—melanoma	0.000664	0.00131	CcSEcCtD
Raloxifene—Headache—Docetaxel—melanoma	0.00066	0.00131	CcSEcCtD
Raloxifene—Nausea—Docetaxel—melanoma	0.000626	0.00124	CcSEcCtD
Raloxifene—HTR2B—Signaling Pathways—MAP2K2—melanoma	4.9e-05	0.000109	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—S100B—melanoma	4.9e-05	0.000108	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CXCL8—melanoma	4.89e-05	0.000108	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HIF1A—melanoma	4.88e-05	0.000108	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARG—melanoma	4.85e-05	0.000108	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP17A1—melanoma	4.75e-05	0.000105	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP1B1—melanoma	4.72e-05	0.000105	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CA—melanoma	4.71e-05	0.000104	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.69e-05	0.000104	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB4—melanoma	4.68e-05	0.000104	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL2—melanoma	4.67e-05	0.000104	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KDR—melanoma	4.67e-05	0.000103	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TERT—melanoma	4.66e-05	0.000103	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RAC1—melanoma	4.64e-05	0.000103	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN2B—melanoma	4.64e-05	0.000103	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	4.63e-05	0.000103	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.58e-05	0.000101	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FN1—melanoma	4.49e-05	9.95e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CD86—melanoma	4.49e-05	9.95e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GNA11—melanoma	4.49e-05	9.94e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HIF1A—melanoma	4.45e-05	9.87e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EDN1—melanoma	4.45e-05	9.87e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NOTCH1—melanoma	4.4e-05	9.74e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PHGDH—melanoma	4.4e-05	9.74e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LUM—melanoma	4.4e-05	9.74e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—FASN—melanoma	4.39e-05	9.73e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CG—melanoma	4.37e-05	9.68e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—melanoma	4.36e-05	9.66e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGF1—melanoma	4.35e-05	9.65e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CSF2—melanoma	4.35e-05	9.65e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC5A5—melanoma	4.32e-05	9.57e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HPSE—melanoma	4.31e-05	9.55e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CD80—melanoma	4.31e-05	9.54e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CG—melanoma	4.3e-05	9.53e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APC—melanoma	4.3e-05	9.53e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIT—melanoma	4.3e-05	9.53e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—NRAS—melanoma	4.3e-05	9.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—E2F1—melanoma	4.26e-05	9.44e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KDR—melanoma	4.26e-05	9.44e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGF—melanoma	4.25e-05	9.42e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CUBN—melanoma	4.23e-05	9.38e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PDGFRA—melanoma	4.22e-05	9.34e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARG—melanoma	4.21e-05	9.34e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ITGB3—melanoma	4.17e-05	9.25e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PRKCA—melanoma	4.17e-05	9.25e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GNAQ—melanoma	4.17e-05	9.24e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CD44—melanoma	4.17e-05	9.24e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—IL6—melanoma	4.17e-05	9.24e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK3—melanoma	4.12e-05	9.12e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FN1—melanoma	4.1e-05	9.09e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SPP1—melanoma	4.09e-05	9.07e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SDHD—melanoma	4.09e-05	9.06e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—BSG—melanoma	4.09e-05	9.06e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CSPG4—melanoma	4.09e-05	9.06e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.08e-05	9.05e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAP2K2—melanoma	4.08e-05	9.04e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.05e-05	8.97e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—BRAF—melanoma	4.04e-05	8.95e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NOTCH1—melanoma	4.01e-05	8.89e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP1B1—melanoma	4e-05	8.86e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GPAM—melanoma	3.96e-05	8.77e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—melanoma	3.94e-05	8.74e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1—melanoma	3.94e-05	8.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CD80—melanoma	3.93e-05	8.71e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—melanoma	3.92e-05	8.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CG—melanoma	3.92e-05	8.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APC—melanoma	3.92e-05	8.7e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—melanoma	3.92e-05	8.7e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK1—melanoma	3.92e-05	8.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—melanoma	3.92e-05	8.68e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCB1—melanoma	3.89e-05	8.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—melanoma	3.88e-05	8.6e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGF—melanoma	3.88e-05	8.6e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RAC1—melanoma	3.87e-05	8.57e-05	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—melanoma	3.85e-05	8.53e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CD—melanoma	3.84e-05	8.51e-05	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—melanoma	3.8e-05	8.43e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAP2K1—melanoma	3.8e-05	8.43e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ALB—melanoma	3.79e-05	8.4e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CD—melanoma	3.78e-05	8.37e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK3—melanoma	3.76e-05	8.33e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—melanoma	3.74e-05	8.29e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—melanoma	3.71e-05	8.22e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—melanoma	3.7e-05	8.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BRAF—melanoma	3.69e-05	8.17e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FGF2—melanoma	3.62e-05	8.02e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1—melanoma	3.59e-05	7.96e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PRKCA—melanoma	3.58e-05	7.93e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK1—melanoma	3.58e-05	7.92e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—melanoma	3.57e-05	7.92e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ERCC2—melanoma	3.55e-05	7.87e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KDR—melanoma	3.55e-05	7.86e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.53e-05	7.82e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAP2K1—melanoma	3.47e-05	7.69e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CD—melanoma	3.45e-05	7.64e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—melanoma	3.42e-05	7.57e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FN1—melanoma	3.42e-05	7.57e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—melanoma	3.4e-05	7.53e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MDM2—melanoma	3.39e-05	7.5e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—melanoma	3.38e-05	7.48e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLA2G6—melanoma	3.37e-05	7.46e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CB—melanoma	3.35e-05	7.41e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NOTCH1—melanoma	3.34e-05	7.41e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—melanoma	3.34e-05	7.4e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—melanoma	3.32e-05	7.35e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FGF2—melanoma	3.3e-05	7.32e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CB—melanoma	3.29e-05	7.3e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCB1—melanoma	3.29e-05	7.3e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CD80—melanoma	3.27e-05	7.26e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APC—melanoma	3.27e-05	7.24e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—melanoma	3.27e-05	7.24e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CG—melanoma	3.27e-05	7.24e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGF—melanoma	3.23e-05	7.16e-05	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—melanoma	3.22e-05	7.14e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CXCL8—melanoma	3.17e-05	7.01e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—melanoma	3.14e-05	6.97e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—melanoma	3.1e-05	6.88e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1B—melanoma	3.09e-05	6.85e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MDM2—melanoma	3.09e-05	6.85e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BRAF—melanoma	3.07e-05	6.81e-05	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—melanoma	3.06e-05	6.78e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—melanoma	3.05e-05	6.75e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PRKCA—melanoma	3.03e-05	6.72e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—melanoma	3.03e-05	6.71e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—melanoma	3.03e-05	6.7e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—VCAN—melanoma	3.02e-05	6.7e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL6—melanoma	3.01e-05	6.67e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CB—melanoma	3.01e-05	6.66e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ERCC2—melanoma	3.01e-05	6.66e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1—melanoma	2.99e-05	6.63e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—melanoma	2.95e-05	6.53e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—melanoma	2.92e-05	6.47e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAP2K1—melanoma	2.89e-05	6.41e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—melanoma	2.89e-05	6.41e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CXCL8—melanoma	2.89e-05	6.4e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CD—melanoma	2.87e-05	6.37e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—melanoma	2.87e-05	6.36e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—melanoma	2.86e-05	6.34e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1A—melanoma	2.85e-05	6.32e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—melanoma	2.85e-05	6.31e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MAPK3—melanoma	2.84e-05	6.3e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NFKB1—melanoma	2.83e-05	6.28e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1B—melanoma	2.82e-05	6.25e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CG—melanoma	2.8e-05	6.21e-05	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—melanoma	2.79e-05	6.19e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—melanoma	2.78e-05	6.15e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—melanoma	2.77e-05	6.13e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—melanoma	2.77e-05	6.13e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—melanoma	2.76e-05	6.12e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FGF2—melanoma	2.75e-05	6.1e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL6—melanoma	2.75e-05	6.09e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARG—melanoma	2.71e-05	6e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—melanoma	2.69e-05	5.96e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—melanoma	2.67e-05	5.91e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—melanoma	2.61e-05	5.79e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1A—melanoma	2.6e-05	5.77e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—melanoma	2.6e-05	5.76e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NFKB1—melanoma	2.59e-05	5.73e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MDM2—melanoma	2.57e-05	5.7e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—melanoma	2.57e-05	5.7e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP17A1—melanoma	2.55e-05	5.65e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—STAT3—melanoma	2.55e-05	5.64e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—melanoma	2.54e-05	5.63e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—melanoma	2.54e-05	5.62e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—melanoma	2.53e-05	5.62e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CB—melanoma	2.5e-05	5.55e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.49e-05	5.52e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CD—melanoma	2.47e-05	5.46e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ALB—melanoma	2.43e-05	5.39e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK3—melanoma	2.43e-05	5.39e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GNA11—melanoma	2.41e-05	5.34e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CXCL8—melanoma	2.41e-05	5.33e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CG—melanoma	2.37e-05	5.26e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—melanoma	2.37e-05	5.24e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—FASN—melanoma	2.36e-05	5.22e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1B—melanoma	2.35e-05	5.21e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—melanoma	2.35e-05	5.2e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—STAT3—melanoma	2.32e-05	5.15e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC5A5—melanoma	2.32e-05	5.14e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—melanoma	2.32e-05	5.14e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK1—melanoma	2.31e-05	5.13e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—melanoma	2.31e-05	5.13e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—melanoma	2.3e-05	5.1e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—melanoma	2.3e-05	5.1e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARG—melanoma	2.29e-05	5.08e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—melanoma	2.24e-05	4.97e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GNAQ—melanoma	2.24e-05	4.96e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CD44—melanoma	2.24e-05	4.96e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—melanoma	2.22e-05	4.92e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK3—melanoma	2.22e-05	4.92e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—melanoma	2.19e-05	4.84e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—melanoma	2.18e-05	4.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1A—melanoma	2.17e-05	4.81e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—melanoma	2.16e-05	4.8e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—melanoma	2.16e-05	4.78e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NFKB1—melanoma	2.15e-05	4.77e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CB—melanoma	2.15e-05	4.76e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1B1—melanoma	2.15e-05	4.76e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—melanoma	2.13e-05	4.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK1—melanoma	2.11e-05	4.68e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—melanoma	2.11e-05	4.68e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CD—melanoma	2.09e-05	4.62e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALB—melanoma	2.06e-05	4.57e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—melanoma	2.04e-05	4.52e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—melanoma	2.01e-05	4.45e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—melanoma	2e-05	4.42e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—melanoma	1.95e-05	4.33e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—melanoma	1.94e-05	4.3e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—STAT3—melanoma	1.94e-05	4.29e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—melanoma	1.93e-05	4.28e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—melanoma	1.92e-05	4.25e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—melanoma	1.86e-05	4.12e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—melanoma	1.86e-05	4.11e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK3—melanoma	1.85e-05	4.1e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—melanoma	1.83e-05	4.06e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CB—melanoma	1.82e-05	4.03e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—melanoma	1.8e-05	3.99e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—melanoma	1.8e-05	3.99e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL6—melanoma	1.78e-05	3.94e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—melanoma	1.77e-05	3.93e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCB1—melanoma	1.77e-05	3.92e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK1—melanoma	1.76e-05	3.9e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—melanoma	1.76e-05	3.9e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—melanoma	1.7e-05	3.76e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—melanoma	1.67e-05	3.69e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—melanoma	1.66e-05	3.68e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—melanoma	1.64e-05	3.63e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PRKCA—melanoma	1.63e-05	3.61e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL6—melanoma	1.62e-05	3.6e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ERCC2—melanoma	1.61e-05	3.58e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—melanoma	1.57e-05	3.48e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—melanoma	1.53e-05	3.38e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—melanoma	1.5e-05	3.32e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—melanoma	1.48e-05	3.27e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—melanoma	1.41e-05	3.13e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL6—melanoma	1.35e-05	3e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—melanoma	1.31e-05	2.9e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CG—melanoma	1.27e-05	2.82e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—melanoma	1.25e-05	2.76e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARG—melanoma	1.23e-05	2.73e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CD—melanoma	1.12e-05	2.48e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—melanoma	1.11e-05	2.46e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALB—melanoma	1.11e-05	2.45e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—melanoma	1.07e-05	2.37e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CB—melanoma	9.76e-06	2.16e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—melanoma	9.67e-06	2.14e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—melanoma	9.06e-06	2.01e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—melanoma	8.44e-06	1.87e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—melanoma	5.95e-06	1.32e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—melanoma	4.86e-06	1.08e-05	CbGpPWpGaD
